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before that was followed by a progressive insomnia, also asso-
ciated with behavioral and mood lability.
General physical examination, laboratory tests, fundoscopic
analysis, brain CT scan, and MRI were unremarkable. The EEG
showed only a diffuse slowing, mainly on anterior regions, with
preserved posterior alpha rhythm on eye closure. On admission,
facial dyskinesias and choreo-athetoid movements of the limbs
(Video, Segment 1) were observed. These hyperkinesias were later
seen during periods of unresponsiveness resembling sleep. The
epileptic nature of these episodes was ruled out by means of
video-EEG recordings, that documented a concomitant EEG pat-
tern intermediate between sleep and wakefulness suggestive of a
“Status Dissociatus” (Video, Segment 2).4 A short-stepped gait,
characterized by festination and freezing of gait (FOG), was also
noticed (Video, Segment 3).
CSF and serum analysis revealed the presence of anti-
NMDAR antibodies. Intravenous and oral steroids combined
with repeated intravenous immunoglobulin led to a gradual
normalization of clinical and EEG abnormalities. Repeated
laboratory and radiological screening for neoplasms as well
as neurological and cognitive follow-up did not reveal any
abnormalities in the following 3 years.
Anti-NMDAR encephalitis constitutes one of themost common
causes of encephalitis in children, in whom it can present with a
broad spectrum of movement disorders.3 Gait disorders have been
reported particularly in children, also as a presenting sign, and
have been characterized by the presence of ataxia, unilateral weak-
ness with circumduction or spasticity.3,5,6 Our case presented the
typical sequence effect of step length noted in adults with FOG
and probably represents the youngest case of such phenomena.7
Because anti-NMDAR encephalitis can present with vague
symptoms, diagnosis and treatment are often delayed. Our case
highlights that gait disturbance should raise the concern for anti-
NMDAR encephalitis in young children, particularly when
observed in the setting of other neurological abnormalities.
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Monitoring Subthalamic
Oscillations for 24 Hours in a
Freely Moving Parkinson’s
Disease Patient
Adaptive deep brain stimulation (DBS) devices aim to per-
sonalize stimulation delivery by following the current state of
symptom-speciﬁc neural signals during different activities of
daily living (walking, sleeping, etc.). This approach is not yet
suitable for clinical practice, and groundwork is needed. The
ﬁrst essential steps for establishing adaptive DBS comprise the
capacity for measurements in chronically implanted patients
(to avoid the “stunning effect”)1 and for prolonged recordings
not corrupted by artifacts.2,3
Our centers teamed up to address these challenges and were
able to successfully record the bilateral subthalamic local ﬁeld
potentials for 24 hours in 1 patient chronically implanted for
Parkinson’s disease (ClinicalTrials.gov: NCT03422757). The
recordings were performed in a 55-year-old woman suffering
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from akinetic-rigid PD for 8 years and admitted to the hospital
for battery replacement after 4 years of subthalamic DBS (Activa
PC, lead model 3389; Medtronic). After 30-minute recordings
(baseline) in stim-off/meds-off condition (overnight pausing of all
dopaminergic medication), we set the new AlphaDBS device
(Newronika Srl)1 to the chronically active parameters (left: 3-C+,
4.8 V, 60 μs, 170 Hz; right: 11-C+, 5.5 V, 60 μs, 170 Hz).
Recordings lasted for 24 hours continuously over 2 days,
during which the patient freely performed everyday life activi-
ties and had approximately 6 hours of sleep at night. Recordings
were performed during active stimulation in a differential
conﬁguration (left: contacts 0-1; right: contacts 8-9) and stored
on the device.1 We chose these contacts as they showed the high-
est peak in the β-frequency range. Despite active stimulation, we
observed clear modulation of the low β-frequency range
(13-20 Hz) following levodopa intake.4 In this band, we
recorded the highest interhemispheric subthalamic cross-
frequency amplitude-amplitude coupling (r = 0.62, P < 0.0001)
during the daytime, which diminished during night sleep (Fig. 1).
The clinical efﬁcacy of DBS was maintained throughout the
experiment, with stable improvement ranging between 30%
and 37% (with respect to the baseline MDS-UPDRS part III
FIG. 1. Time plot (upper row) and power spectral density (lower row) of local ﬁeld potentials (LFPs) recorded in the left (A) and the right (B) subthalamic nucleus
(STN) in baseline condition. Time-frequency plot of LFPs in the range 5-35 Hz recorded in the left (C) and the right (D) STN during 24 hours of cDBS. Red dot
indicates when deep brain stimulation was activated and green dots the intake of levodopa. Nighttime sleep is shown between the 2 pink dots. Interhemispheric
subthalamic cross-frequency amplitude-amplitude coupling during daytime (E) and nighttime sleep (F).
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score of 39/108), which was similar to that experienced by the
patient at home (36% improvement in stim-on/meds-off at
enrollment visit). During the study, the patient continued the
home medication regimen and took 1 pill of fast-acting oral
levodopa/benserazide 100/25 mg on 2 occasions. Levodopa
improved parkinsonian symptoms by 5 points on the MDS-
UPDRS part III score, without adverse events (i.e., dyskine-
sias). No adverse events or complaints by the patient were
reported. The Ethical Committee approved the study, and all
patients gave written informed consent.
Our results prove the feasibility of prolonged recordings
(up to 24 hours) in freely moving, chronically stimulated
patients. They further corroborate the hypothesis that oscilla-
tions in the β-frequency range might be used as a levodopa-
related biomarker for adaptive DBS paradigms, as they are
present during active stimulation and years after surgery. We
also provide for the ﬁrst time preliminary evidence that inter-
hemispheric subthalamic coupling changes between wakeful-
ness and sleep can be monitored and possibly serve as an
additional behavior-speciﬁc biomarker. These ﬁndings pave
the way for testing different adaptive stimulation paradigms
for STN-DBS and prompt a more accurate deﬁnition of
symptom-related and behavior-speciﬁc biomarkers in PD.5
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Minimal Clinically Important
Difference for the Quality of Life
in Essential Tremor Questionnaire
Essential tremor (ET) can considerably impair health-related
quality of life (HRQoL). Disability and impairment, related to
motor and nonmotor symptoms of the disease, can be speciﬁ-
cally captured by the Quality of Life in Essential Tremor Ques-
tionnaire (QUEST).1 Although this instrument is increasingly
used in clinical practice and research, its minimal clinically
important difference (MCID) has not yet been established. We
therefore aimed to determine these threshold values that may
provide guidance on judging the clinical relevance of changes
associated with both disease progression and various treatment
options.
A total of 248 consecutive patients with ET attending the
Department of Neurology, Pécs, Hungary, between June 2013
and December 2018 were enrolled. In addition to demographic,
medication, and disease-related data, the validated Hungarian
version of the QUEST2 was assessed at baseline. Disease severity
was determined by the QUEST Summary Index (QUEST-SI) as
mild (≤11.25), moderate (11.26-20.35), and severe (>20.35).2
The major neurocognitive disorder was an exclusion criterion
(Montreal Cognitive Assessment score <20.5). At follow-up
visits, the QUEST-SI was reassessed, and patients rated the per-
ceived changes in ET-related difﬁculties since the last visit on the
Patient-rated Global Impression of Improvement (PGI-I) scale.
The methods for calculating MCID were previously described in
full detail elsewhere.3
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